Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura

Liu, Hongyun; Ouyang, Xianfeng; Li, Yiqing; Zeng, Hua; Wang, Xiuju; Xie, Shuangfeng; Nie, Danian; Xiao, Jie; Wei, Jing; Wu, Yudan; Su, Yin; Ma, Liping

doi:10.1016/j.thromres.2013.04.025

Cited by 31 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…% than those with other genotypes. This reflects a state of TH1 polarization in childhood ITP as previously shown . This bias even returning to a dominant TH1 response was demonstrated in relapsed patients after corticosteroid treatment .…”

Section: Discussionsupporting

confidence: 80%

IL‐10 polymorphisms and T‐cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population

Soliman

Helwa

Fath-Allah

et al. 2018

APMIS

View full text Add to dashboard Cite

The aim is to study IL-10 polymorphisms and IL-10 level and assess their relation to T-cell subsets in childhood immune thrombocytopenia (ITP). In all, 40 (25 acute, 15 chronic) ITP child patients were investigated at time of presentation, compared to 15 healthy, age- and gender-matched controls and followed up for 1 year to determine chronic cases. Studying the effect of IL-10 promoter polymorphism was done by PCR-RFLP, IL-10 level was determined by ELISA, natural killer cells and T-cell subsets were evaluated by flow cytometry. Subjects with IL-10 promoter (1082 AA and 592 AA) genotypes had lower IL-10 levels and had lower CD4%, higher CD8%, lower CD4/CD8 ratio and lower T-reg%. IL-10 polymorphisms had no effect on NK%. IL-10 serum levels and IL-10 promoter polymorphic genotype frequencies are not different between ITP cases and controls; however, in ITP patients, IL-10 promoter (1082 AA and 592 AA) genotypes and associated lower CD4, higher CD8, lower CD4/CD8 ratio is associated with more severe thrombocytopenia at presentation and had a poorer response to first-line treatment. Patients with lower T-reg cells had a higher tendency to develop chronic ITP. IL-10 level and polymorphisms as well as disturbed T-cell subsets percentages are demonstrable effectors of immune dysfunction in ITP and can affect the presentation and outcome of childhood ITP.

show abstract

Section: Discussionsupporting

confidence: 80%

IL‐10 polymorphisms and T‐cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population

Soliman

Helwa

Fath-Allah

et al. 2018

APMIS

View full text Add to dashboard Cite

show abstract

“…Previous study demonstrated that IL-23 can be induced by Toll-like receptor (TLR) agonists and interactions with T cells (CD40/CD40L interaction) [ 24 ]. Liu et al found that TLR4 was abnormal expression in ITP patients and demonstrated that TLR4 in combination with FcγRII could cause DCs to express cytokines IL-23 then promote effector Th17 cell responses [ 25 ]. These may suggest that the elevated of IL-23 may cause by abnormal TLR, but the exact mechanism need further study.…”

Section: Discussionmentioning

confidence: 99%

The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia

Zhang

Wang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

BackgroundPrimary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with an unclear etiology. This study aims to investigate the role of IL-23/Th17 pathway in patients with ITP.MethodThe gene expressions of IL-17, IL-23 and their receptors in ITP patients and healthy controls were analyzed by quantitative real-time PCR. ELISA was used to test the IL-17 and IL-23 levels in plasma. Flow cytometry was used to detect the frequency of Th17 cells. The correlation between plasma IL-23 and IL-17 levels, Th17 cells, platelets were analyzed. The level of Th17-related cytokines was measured by ELISA following stimulation with IL-23. Subsequently, the IL-23 and IL-17 levels were measured in patients post-treatment.ResultsThe PBMCs of ITP patients showed increased mRNA expression levels in each of the following: IL-23p19, IL-12p40, IL-23R, IL-12Rβ1, IL-17A, IL-17F, and RORC. In addition, elevated Th17 cells and plasma IL-17, IL-23 levels were also observed in these ITP patients. Furthermore, it was found that IL-23 levels in plasma are positively correlated with IL-17 levels and Th17 cells, yet negatively correlated with platelet count. Following IL-23 stimulation in vitro, IL-17 levels showed significant elevation. Furthermore, both IL-23 and IL-17 levels decreased after effective treatment.ConclusionThe IL-23/Th17 pathway may be involved in the pathogenesis of ITP through enhancement of the Th17 response. Moreover, our results suggest that the IL-23/Th17 pathway is a potential therapeutic target in future attempts of ITP treatment.

show abstract

“…Indeed, ITP is considered a Th1/Th17 type of disease . Investigators have shown that ITP is associated with an increase in Th1‐ and Th17‐cell cytokine profiles, including IL‐2, IL‐16, IL‐17, and IFN‐γ . Also, because it has previously been reported that there are strain‐specific differences in responses to IVIG in mouse models, we evaluated cytokine profiles in two different mouse strains, BALB/c and C57BL/6J (B6), commonly used for these experimental studies.…”

Section: Discussionmentioning

confidence: 99%

“…In human ITP, patients have extravascular‐mediated destruction of autoantibody‐sensitized platelets (PLTs) as well as impaired production of PLTs . This condition is associated with an inflammatory state that is manifest by increased Th17 and Th1 cells and increased production of proinflammatory cytokines including interleukin (IL)‐1α, IL‐2, IL‐6, IL‐16, IL‐17, IL‐23, and interferon (IFN)‐γ 17‐26. The majority of published mouse models of human ITP use passive administration of a rat monoclonal PLT antibody to initiate and maximize the thrombocytopenia.…”

mentioning

confidence: 99%

Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain

2014

View full text Add to dashboard Cite

show abstract

Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura

Cited by 31 publications

References 28 publications

IL‐10 polymorphisms and T‐cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population

IL‐10 polymorphisms and T‐cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population

The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia

Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain

Contact Info

Product

Resources

About